Myriad Genetics (MYGN) Enterprise Value (2016 - 2025)
Myriad Genetics (MYGN) has disclosed Enterprise Value for 17 consecutive years, with -$149.6 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value fell 46.09% to -$149.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$149.6 million, a 46.09% decrease, with the full-year FY2025 number at -$149.6 million, down 46.09% from a year prior.
- Enterprise Value was -$149.6 million for Q4 2025 at Myriad Genetics, down from -$145.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$74.4 million in Q2 2025 to a low of -$366.2 million in Q3 2021.
- A 5-year average of -$155.8 million and a median of -$131.2 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: crashed 128.3% in 2021, then soared 70.57% in 2023.
- Myriad Genetics' Enterprise Value stood at -$338.8 million in 2021, then skyrocketed by 66.09% to -$114.9 million in 2022, then decreased by 22.63% to -$140.9 million in 2023, then grew by 27.32% to -$102.4 million in 2024, then plummeted by 46.09% to -$149.6 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's Enterprise Value are -$149.6 million (Q4 2025), -$145.4 million (Q3 2025), and -$74.4 million (Q2 2025).